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The human serine proteases granzymes A and B are expressed in cytotoplasmic granules of activated 
cytotoxic T lymphocytes and natural killer cells. Recombinant granzyme A and granzyme B proteins were 
produced in bacteria, purified and then used to raise specific mouse monoclonal antibodies. Seven 
monoclonal antibodies (mAb) were raised against granzyme A, which all recognized the same or 
overlapping epitopes. They reacted specifically in an immunoblot of interleukin-2 (IL-2) stimulated 
PBMNC with a disulfide-linked homodimer of 43 kDa consisting of 28 kDa subunits. Seven mAb against 
granzyme B were obtained, which could be divided into two groups, each recognizing a different epitope. 
On an immunoblot, all mAb reacted with a monomer of 33 kDa protein. By immunohistochemistry, these 
mAb could be used to detect granzymes A and B expression in activated CTL and NK cells. The 
availability of these mAb may facilitate studies on the role of human cytotoxic ells in various immune 
reactions and may contribute to a better understanding of the role of granzymes A and B in the cytotoxic 
response in vivo. 
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Introduction 
Activated cytotoxic T lymphocytes (CTL) and 
natural killer (NK) cells are the effector cells in 
major histocompatibility complex (MHC)-re- 
stricted and in non-MHC-restricted cellular cyto- 
toxicity, respectively. These cytotoxic reactions 
are important in the elimination of tumor cells 
and virus infected cells and for the process of 
allograft rejection. The cytoplasm of CTL and 
NK cells contains pecialized, so-called cytotoxic 
granules, which are able to lyse susceptible tar- 
gets. The major components of these cytotoxic 
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granules are the pore forming protein 'perforin' 
(Lichtenheld et al., 1988), proteoglycans and a 
unique family of highly homologous serine pro- 
teases, termed 'granzymes'. 
In humans three serine proteases have been 
identified in the cytotoxic granules at the protein 
level: granzyme A, granzyme B and granzyme 3
(Krahenbuhl et al., 1988; Hameed et al., 1988). 
Full length cDNA has been cloned for granzymes 
A (Gershenfeld et al., 1988) and B (Trapani et 
al., 1988a; Caputo et al., 1988) but not for 
granzyme 3. Granzymes are synthesized as inac- 
tive precursor molecules containing a signal (pre-) 
peptide and a very short propeptide. In the cyto- 
toxic granules granzyme A is present as a disul- 
fide linked 50 kDa homodimer while granzyme B
consists of a 29 kDa monomer. Both are stored as 
fully processed active enzymes, i.e., without the 
pre- and pro-peptide (Krahenbuhl et al., 1988). 
In vitro studies have demonstrated that (1) 
granzyme A is secreted from CTL upon T cell 
receptor stimulation (Krahenbuhl et al., 1988); (2) 
lysis by CTL clones and isolated granules i  inhib- 
ited by pretreatment with serine protease in- 
hibitors (Hudig et al., 1991); and (3) the expres- 
sion of granzyme A and perforin is correlated 
with the functional cytolytic potency in vitro 
(Garcia-Sanz et al., 1990). These findings uggest 
involvement of granzymes in the lytic process. 
Several investigators using in situ hybridisation, 
have provided evidence that in vivo expression of 
perforin and granzymes i found in inflammatory 
tissue in the mouse as well as in the human 
(reviewed by Griffiths and Mueller, 1991). 
Studies on the role of granzymes in human 
disease, as markers for activated cytotoxic ells, 
would be facilitated by the availability of specific 
antibodies against hese proteases. Here we re- 
port the production and characterization f mAb 
raised against recombinant human granzymes A 
and B, reacting with the natural proteins. 
Materials and methods 
Cloning of granzymes A and B cDNA 
To obtain the cDNAs coding for the mature 
granzymes A and B (i.e., without the pre- and 
propeptide) respectively, specific primers were 
prepared based on the published cDNA sequence 
for granzyme A (Gershenfeld et al., 1988) and B 
(Trapani et al., 1988a), containing the appropri- 
ate restriction sites. Polymerase chain reaction 
(PCR) amplification was performed on first strand 
cDNA prepared from mRNA extracted from 
human peripheral blood mononuclear ceils 
(PBMNC), cultured for 3 days at a concentration 
of 0.5 x 106 cells/ml in Iscove's modified Dul- 
becco's medium (IMDM) supplemented with 5% 
(v/v) heat-inactivated fetal calf serum (FCS), 
streptamycin, penicillin, /3-mercaptoethanol and 
50 U of IL-2 (Cetus, Emeryville, CA) per ml. The 
amplified cDNA fragments were isolated, di- 
gested with the appropriate restriction enzymes 
and ligated into similar restriction sites in the 
vector PET 3b, such that its expression was under 
the control of the T7 RNA polymerase promotor. 
Plasmid DNA isolation, restriction enzyme diges- 
tion conditions and agarose gel electrophoresis 
were performed as described (Sambrook et al., 
1989). The authenticity of the cloned cDNAs was 
confirmed by nucleotide sequence analysis 
(Sequenace kit, USB, Cleveland, OH). 
Production and purification of recombinant 
granzymes A and B in E. coli 
The expression plasmids PET 3b/granzyme A 
and PET 3b/granzyme B were used to transform 
E. coli BL 21(DE3) which expresses T7 RNA 
polymerase under control of the inducible lac UV 
5 promotor. Single colonies of E. coli, trans- 
formed with either PET3b/granzyme A or 
PET3b/granzyme B, were used to inoculate 5 ml 
LC medium supplemented with ampicillin (100 
txg/ml). The bacteria were grown at 37°C until 
the absorbance at 550 nm was 0.6. Then isopropyl 
/3-t)-thiogalactopyranoside (IPTG, Sigma) was 
added to a final concentration f 1 mM, and the 
E. coli were allowed to grow for another 2 h. In 
general, the pellet of 100 ml E. coli was resus- 
pended in TE (10 mM Tris-HCl, pH 7.4, 10 mM 
EDTA), subjected to three freeze/thaw cycles 
and lysed by sonication. Recombinant proteins 
were pelleted by centrifugation, separated by 
SDS-PAGE (12.5%) and electroeluted from the 
gel using the Schleicher and Schiill protein elu- 
tion apparatus. SDS was removed from the pro- 
tein preparation as previously described (Konigs- 
berg and Henderson, 1983). These preps were 
used for immunization (see further). After this 
SDS extraction procedure the purified proteins 
were insoluble. Therefore this material was soni- 
cated for 30 s prior to use in coating of ELISA 
plates (at a concentration f 3 p.g/ml in PBS). 
Production and purification of mAb against 
granzymes A or B 
BALB/c mice were immunized subcuta- 
neously with 50 /xg of purified recombinant 
granzyme A or granzyme B emulsified in com- 
plete Freund's adjuvant (CFA) followed by three 
subsequent injections of 50 /zg of recombinant 
protein in incomplete Freund's adjuvant (IFA) at 
intervals of 2 weeks. 4 days after the last booster 
injection, spleen cells were isolated and fused 
with mouse myeloma Sp2/0-Ag14 cells under 
standard conditions. Resulting hybridomas were 
screened for anti-granzyme A or anti-granzyme B 
antibody production by an ELISA procedure us- 
ing purified recombinant granzymes A and B and 
horseradish peroxidase-coupled goat anti-mouse 
IgG. Antibody-producing hybridomas were cloned 
by limiting dilution and cultured in bulk. All mAb 
were purified by protein G affinity chromatogra- 
phy (Pharmacia Fine Chemicals, Uppsala, Swe- 
den). 
Immunoblotting 
Recombinant granzymes A and B as well as 
cell lysates of IL-2 stimulated PBMNC were used 
in an immunoblot to test the specificity of the 
monoclonal antibodies obtained. The pellet of a 
bacterial suspension (200 /xl) was lysed and the 
insoluble fraction, containing the recombinant 
proteins, was obtained by high speed centrifuga- 
tion as described above. The cell lysates were 
obtained as follows: 40 X 10 6 PBMNC (stimu- 
lated for 7 days with 1000 U/ml IL-2) were 
resuspended in 1 ml of 10 mM Tris-HC1, pH 8.0, 
150 mM NaC1, 1% (w/v) NP40 (Sigma, St Louis, 
Mo), gently mixed and left for 30 min in an ice 
bath. The mixture was then centrifuged for 10 
min at 200 xg  (4°C) and the supernatant was 
stored at -70°C until used. Briefly, SDS-PAGE 
separated recombinant proteins and lysate were 
transferred onto nitrocellulose sheets. Sheets 
were preincubated with PBS, 5% (w/v) non fat 
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dry milk, 0.1% (w/v) Tween 20 for 30 min, and 
subsequently with the appropriate primary anti- 
body diluted in the same buffer for 2 h. After 
washing three times with PBS, 0.1% (w/v) Tween 
20 for 10 min, the blot was incubated with HRP- 
conjungated goat anti-mouse IgG for 2 h, washed 
as before and stained by addition of 4-chloro-1- 
naphthol (Sigma). 
Immunofluorescence staining of single cells and 
conjugates 
K562 cells and NK cell clone 76, generously 
provided by Dr. R.L.H. Bolhuis (Rotterdam, 
Netherlands), were cultured as described (Rado- 
levi6 et al., 1990; Bolhuis et al., 1984). NK-target 
cell conjugates were formed by mixing equal vol- 
umes of NK and K562 cells, each at a concentra- 
tion of 1-2 x 106 cells/ml in RPMI 1640 supple- 
mented with Hepes, 10% (v/v) FCS, 2 mM L- 
glutamine and antibiotics, followed by centrifuga- 
tion for 5 min at 200 g, resuspension and incuba- 
tion for another 20 min at 37°C. Aliquots of 
1-2 × 105 cells were attached to poly-e-lysine 
(Sigma) coated coverslips and fixed with 4% (w/v) 
paraformaldehyde (10min at room temperature), 
washed twice with PBS and permeabilized using 
methanol (2 min at room temperature). Cover- 
slips were washed with PBS and cells were incu- 
bated with the appropriate mAb (50 /zg/ml) in 
PBS-BSA followed by goat anti-mouse FITC, 1 to 
50 diluted in PBS-BSA, each for 30 min at room 
temperature. After washing, the coverslips were 
sealed and examined with a confocal aser scan- 
ning microscope (CSLM) (Leica Lasertechnik, 
Heidelberg, Germany). The CSLM was equipped 
with an inverted fluorescence microscope (Fluo- 
vert, FU) and an argon-krypton laser. 
Results 
Expression of human recombinant granzymes A
and B proteins 
To obtain purified granzymes A and B for 
immunisation and screening purposes we decided 
to generate recombinant granzymes A and B 
antigen in a prokaryotic expression system. CDNA 
coding for the mature proteases (thus without he 
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pre- and propeptides) was generated by PCR, 
performed on first strand cDNA prepared from 
mRNA of IL-2 stimulated PBMNC (see materials 
and methods section). The nucleotide sequence 
of the mature granzyme A cDNA was completely 
identical to that published by Gershenfeld et al. 
(Gershenfeld et al., 1988). The nucleotide se- 
quence of the granzyme B cDNA was the same as 
that published by Caputo et al. (Caputo et al., 
1988). After the appropriate PCR products were 
cloned into the PET 3b expression vector and 
transfected into DE3 (BL21) bacteria, several 
clones were isolated for each construct, se- 
quenced, and tested for recombinant protein pro- 
duction. Granzyme A and B recombinant protein 
production by the selected clones was analysed by 
SDS-PAGE. After induction of the bacteria con- 
taining the PET 3b/granzyme A or the PET 
3b/granzyme B plasmid proteins were induced 
with M r of approximately 26 and 29 respectively 
(data not shown). These recombinant proteins 
reacted specifically with polyclonal antisera raised 
against granzymes A and B N- and C-terminal 
peptides on immunoblot (data not shown), estab- 
lishing their identity as granzymes A and B, re- 
spectively. Initial experiments indicated that both 
recombinant granzymes were produced in insolu- 
ble form, as so called 'inclusion bodies', and no 
soluble recombinant protein was detected. Ef- 
forts to solubilize and renature both recombinant 
proteins were not successful. Therefore, we puri- 
fied each granzyme by preparative SDS-PAGE 
and obtained highly pure granzymes A and B 
recombinant proteins, with yields of approxi- 
mately 1 mg of granzyme A and 2 mg of granzyme 
B from 100 ml bacterial cultures. 
Characterization of mAb against granzyme A
From one fusion experiment, seven mAb were 
obtained, all of the IgG1 subclass, which were 
positive in the granzyme A ELISA. To determine 
their reactivity towards recombinant granzymes A 
and B the mAb were tested on immunoblot, as is 
shown for one mAb (GrA-8) in Fig. 1A. GrA-8 
reacted only with recombinant granzyme A (lanes 
1 and 2) and not with recombinant granzyme B 
(lanes 3 and 4). Granzyme A present in the 
cytotoxic granules has been reported to consist of 
a 50 kDa disulfide linked homodimer (Krahen- 
buhl et al., 1988). On an immunoblot of non-re- 
duced LAK cell lysates, GrA-8 mAb appeared to 
bind to a protein band with a M r of 43 kDa (Fig. 
1A, lane 5). Under reducing conditions, the mAb 
reacted with a protein band with a M r of 28 kDa. 
The other mAb against granzyme A all reacted in 
the same way as GrA-8 (not shown). Cross-block- 
ing experiments, in which granzyme coated mi- 
crotiter plates were incubated with saturating 
amounts of individual mAb, followed by an incu- 
bation with each of the biotinylated mAb, indi- 
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42.7 - -  
31.0 - -  
21.5 - -  







Fig. 1. Immunoblot analysis showing reactivity of mAb GrA-8 (A) and GrB-4 (B) with granzymes A and B respectively. 
Non-reduced (lane 1) and reduced (lane 2) recombinant granzyme A (200 ng of protein per lane), non-reduced (lane 3) and 
reduced (lane 4) recombinant granzyme B (200 ng of protein per lane) and non-reduced (lane 5) and reduced (lane 6) LAK cell 
lysates (150× 105 cells)were lectrophoresed on SDS gels and transferred onto nitrocellulose sheets. The blot was probed with 
mAb GrA-8 (A lanes 1-6) and with mAb GrB-4 (B lanes 1-6). 
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cated that all mAb against granzyme A competed 
for binding to recombinant granzyme A. Thus, 
the mAb were apparently all directed against he 
same or overlapping epitopes. 
Characterization of mAb against granzyme B
From two fusion experiments, seven mAb 
against granzyme B were obtained, two of IgG2a 
and five of IgG1 subclass. The reactivity on im- 
munoblot of one of these mAb, GrB-4, with re- 
combinant granzymes A and B, respectively, is 
shown in Fig. lB. This mAb only recognized 
recombinant granzyme B (lanes 3 and 4) and not 
recombinant granzyme A (lane 1 and 2). On a 
Western blot of LAK cell lysates, both under 
reducing and non-reducing conditions one pro- 
tein band was detected by GrB-4 mAb (Fig: 1B, 
lanes 5 and 6) that migrated at approximatly 33 
kDa. 
In cross-blocking experiments, at least two 
groups of mAb against granzyme B were distin- 
guished, each apparently recognizing a different 
epitope on granzyme B. 
Immunofluorescent staining of NK-K562 cell con- 
jugates with the mAb 
The results thus far showed that the mAb 
recognized granzyme A and B proteins from IL-2 
stimulated PBMNC on immunoblots. Another 
important application of the mAb against 
granzymes A and B is the detection of both 
proteases in activated CTL or NK cells by im- 
munofluorescence or immunohistochemistry. Fig. 
2 shows that in immunofluorescence staining the 
anti-granzyme mAb could be used to visualize the 
process of granule reorientation in NK cells to- 
ward the K562 target using confocal laser scan- 
ning. Clearly, a polar distribution was seen in the 
NK cell (left), whereas the cytotoxic granules in 
the other were distributed at random in the cyto- 
plasm (right). With mAb GrB-4 similar patterns 
were observed (data not shown). 
Fig. 2. Confocal laserscan of a NK-K562 cell conjugate stained with mAb GrA-8. Equal volumes of NK and K562 cells were 
incubated for 20 rain at 37°C, attached to poly-L-lysine treated coverslips and fixed with 4% paraformaldehyde. Cytototoxic 
granules were visualized by incubating the fixed cells with GrA-8 followed by goat anti-mouse labeled with FITC. 
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Discussion 
Studies on the role of granzymes in cytotoxic 
and other immune reactions would be facilitated 
by the availabilty of specific monoclonal and poly- 
clonal antibodies. Although granzymes A and B 
proteins were purified in 1988 (Krahenbuhl et al., 
1988), and full-length cDNA for both have been 
isolated, until now mAb against human granzymes 
have not been described. Here, we report the 
production of human recombinant granzymes A
and B and the application of these recombinant 
proteins to raise a panel of specific mouse mAb 
directed against granzymes A or B. These anti- 
bodies all reacted with granzymes from activated 
CTL and NK ceils. 
Hameed et al. (1991) used a prokaryotic ex- 
pression system to produce human granzyme B, 
against which exclusively specific polyclonal anti- 
bodies were raised. We used a similar expression 
system to produce sufficient amounts of recombi- 
nant granzymes A and B. The identity of both 
proteins produced by E. coli were confirmed by 
immunoblotting with polyclonal antibodies raised 
against C-terminal and N-terminal peptides of 
each granzyme. Although the recombinant pro- 
teins could not be solubilized, direct coating on 
ELISA plates of the sonicated protein aggregates 
provided an easy and successful method for the 
detection of mAb. On immunoblot the mAb not 
only recognized the recombinant but also the 
natural protein from LAK cells. The M r of the 
natural granzymes A and B proteins detected by 
the mAb corresponded, in general, with those 
described (Krahenbuhl et al., 1988). 
All seven mAb against granzyme A were of the 
IgG1 subclass and recognized the same or over- 
lapping epitopes on the recombinant granzyme A
protein. In contrast, at least two different ypes of 
mAb against granzyme B were obtained, each 
recognizing a different epitope on granzyme B. 
As immunoblotting indicated that the mAb 
detected denatured natural proteins, we further 
studied the application of these mAb in immuno- 
histochemistry. Both mAb against granzymes A
and B bound to cytotoxic granules in formalin 
and in acetone fixed LAK cells (data not shown), 
suggesting that they can be used in double im- 
munohistochemical staining techniques which may 
be valuable for determining the phenotype of 
cells expressing granzymes in vivo. We also 
demonstrated the application of the mAb in con- 
focal laser scanning microscopy to monitor the 
process of granule reorientation in the cytotoxic 
cells. 
In conclusion, we describe the production and 
characterization of mAb against human gran- 
zymes A and B. These mAb (hybridoma cell lines 
available on request) may facilitate studies on the 
role of human cytotoxic eils in various immune 
reactions and in this way may contribute to the 
better understanding of the role of granzymes A
and B in the cytotoxic response in vivo. 
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